Pathogenesis and treatment of renal failure in multiple myeloma (Q34592826)

3 August 2017

1 reference

title

Pathogenesis and treatment of renal failure in multiple myeloma (English)

1 reference

3 August 2017

E Kastritis

1 reference

3 August 2017

Athanasios Dimopoulos

series ordinal

object named as

M A Dimopoulos

1 reference

3 August 2017

L Rosinol

1 reference

3 August 2017

J Bladé

series ordinal

1 reference

3 August 2017

H Ludwig

series ordinal

1 reference

3 August 2017

publication date

5 June 2008

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

1485-1493

1 reference

Renal failure in multiple myeloma. Pathogenesis and prognostic implications

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Renal Failure in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Pathobiology of cast nephropathy from human Bence Jones proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Renal, hematologic and infectious complications in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Nephrotoxic potential of Bence Jones proteins.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Proximal tubular injury in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Renal function in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Molecular mechanisms of amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Clinical aspects of systemic amyloid diseases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Controlled plasma exchange trial in acute renal failure due to multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Treatment of Renal Failure Associated With Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Management of myeloma kidney: an anti-light-chain approach

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

The evolving role of lenalidomide in the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.131

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.131

1 reference

Dimensions Publication ID

3 August 2017

1053102118

0 references

1 reference